C12N 2810/856
From integrins
Official title: from integrins
C12N2810/856 (From integrins) appears on 11 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 9
- Assignees
- 5
- Inventors
- 21
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Viral nanoparticle multimers15 Jul 2025US 12,359,175 B2Case Western Reserve University
- Compositions of nucleic acid-containing nanoparticles for in vivo delivery1 Feb 2022US 11,235,071 B2The Johns Hopkins University
- Viral nanoparticle multimers7 Dec 2021US 11,193,111 B2Case Western Reserve University
- Compositions of a peptide targeting system for treating cancer7 Jun 2016US 9,358,308 B2NanoOncology, Inc.
- Compositions of a peptide targeting system for treating cancer25 Mar 2014US 8,680,045 B2PeptiMed, Inc.
- Viral nanoparticle multimers24 Mar 2022US 2022/0090026 A1Case Western Reserve University
- Compositions of nucleic acid-containing nanoparticles for in vivo delivery28 Jun 2018US 2018/0177892 A1The Johns Hopkins University
- Compositions of nucleic acid-containing nanoparticles for in vivo delivery17 Nov 2016US 2016/0331845 A1The Johns Hopkins University
- Viral nanoparticle multimers17 Dec 2015US 2015/0361402 A1Case Western Reserve University
- Compositions of a Peptide Targeting System for Treating Cancer7 Aug 2014US 2014/0220045 A1NanoOncology, Inc.
Most cited
By later US patents
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996
- Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein58US 5,712,136 AGenVec, Inc. · 1998
- Penton base protein and methods of using same50US 5,731,190 AGenVec, Inc. · 1998
- Short-shafted adenoviral fiber and its use35US 5,962,311 AGenVec, Inc. · 1999
- Vectors and methods for gene transfer to cells24US 6,465,253 B1GenVec, Inc. · 2002